Sign in5 stories
Former CDC director Robert Redfield joins Turn Therapeutics as CSO, and the company will present atopic dermatitis data at a Stifel investor forum on September 23, 2026.
SEC filing (2)
The Nasdaq-listed biotech added the veteran healthcare executive to its board and to the Audit and Compensation Committees effective September 8, 2026.
SEC filing
The Westlake Village biotechnology company reported sales to eight investors under a Rule 506(b) exemption, with first sale dated August 14, 2026.
SEC filing
The company issued the shares under a warrant tied to its 2025 share purchase agreement with GEM, filed August 18, 2026.
SEC filing
Interim results led the company to broaden Stage 2 enrollment criteria while keeping the trial on track for year-end 2026 completion.
SEC filing